Citations

Clear

948 citation(s) found for "Li, Bryan".

Feasibility of Ultrasound-Guided Percutaneous Placement of Peripheral Nerve Stimulation Electrodes and Anchoring During Simulated Movement: Part Two, Upper Extremity
Huntoon, Marc A. , Hoelzer, Bryan C. , Burgher, Abram H., Hurdle, Mark Friedrich B., Huntoon, Elizabeth

Mayo Clinic

Regional Anesthesia & Pain Medicine | October 11, 2025 | Volume: 33 | Issue: 6 | Pages: 558-565

10.1136/rapm-00115550-200811000-00008 Get It

Background and Objectives: Peripheral nerve stimulation (PNS) may provide analgesia for neuropathic pain syndromes in that nerve distribution. PNS electrode placement using ultrasound (US) guidance for upper extremity pain syndromes has not been reported. Existing anchoring technology may allow permanent implantation without significant migration. Methods: Three cadaver midhumeral fresh frozen upper extremity specimens were studied. US scanning was performed, targeting electrode placement at the radial, ulnar, and median nerves. Leads were anchored in the superficial fascia. The targeted nerves were exposed by careful dissection. Visual inspection for gross nerve damage, and electrode proximity to the nerve was performed. After confirmation of adequate lead placement, 2 extremities were sutured and placed in a continuous passive motion (CPM) machine for 21 hours to simulate activity. Each electrode was assessed for migration. Results: Acceptable locations for US-guided electrode placement were: radial nerve approximately 10-14 cm superior to the lateral epicondyle; median nerve approximately 6 cm below the antecubital fossa; and ulnar nerve approximately 9 to 13 cm above the medial epicondyle. One electrode was placed at each site without difficulty. After careful exposure, visual inspection showed no gross nerve damage. Each electrode had at least 2 electrical contacts within 2 mm of the nerve sheath. At CPM termination, only the median nerve electrode on 1 cadaver extremity had migrated significantly. Conclusions: This new minimally invasive approach to lead placement requires further study to determine implantation criteria, optimal locations, anchoring techniques, and electrode design to define best clinical practice.
Reduction in respiratory muscle strength following a series of preparatory and maximal static, dry breath-holds
Hubbard, Colin D. , Vrdoljak, Dario , Cross, Troy J. , Lovering, Andrew T. , Drviš, Ivan, Dujić, Željko , Foretić, Nikola , Duke, Joseph W. , Coombs, Geoff B , Cross, Troy James , Taylor, Bryan J , Lovering, Andrew T , Dujić, Željko , Foretić, Nikola , Duke, Joseph W , Hubbard, Colin D. , Taylor, Bryan J.

Mayo Clinic

Journal of Applied Physiology | October 3, 2025 | Volume: 139 | Issue: 5 | Pages: 1235-1245

10.1152/japplphysiol.00256.2025 | PMID 41042814 Get It

Respiratory muscle fatigue could occur following involuntary breathing movements during maximal breath-holds. We measured respiratory muscle strength pre and post three preparatory and maximal breath-holds. We found significant reductions in diaphragm strength and total inspiratory and expiratory strength in some, but not all, divers. Divers that had respiratory muscle fatigue had a lower pseudo O 2 delivery (HR × [Formula: see text]) during the struggle phase. This suggests that reduced oxygen delivery may contribute to respiratory muscle fatigue during a breath-hold.
P17.34.B BELZUTIFAN IN CLINICAL PRACTICE: OUTCOMES AND SAFETY IN A REAL-WORLD COHORT OF PATIENTS WITH VHL-ASSOCIATED NEOPLASMS
Galloway, Taylor , Schultz, Sydney , Thomsen, Anna, Ruff, Michael W. , Uhm, Joon H. , Carabenciov, Ivan D. , Jones, James E., Caron, Samantha, Iezzi, Raymond , Mrugała, Maciej M. , Porter, A B, Pagliaro, Lance C. , Dronca, Roxana , Pichurin, Pavel N. , Sonbol, Bassam Bassam, Riegert‐Johnson, Douglas L. , Dhamija, Rhadika, Orme, Jacob J. , Halfdanarson, Thor R, Hobday, Timothy J. , Patrick, M., Ser, Merve Hazal , Karbhari, Nishika , Neth, Bryan J. , Lachance, Daniel Honore , Riaz, Irbaz Bin , Borad, Mitesh J. , Patrick, M W, Sener, Uğur

Mayo Clinic

Neuro-Oncology | October 3, 2025 | Volume: 27 | Issue: Supplement_3 | Pages: iii163-iii163

10.1093/neuonc/noaf193.550 Get It

Abstract BACKGROUND Von Hippel-Lindau (VHL) disease is a hereditary cancer syndrome characterized by development of multiple neoplasms, including central nervous system (CNS) hemangioblastomas, renal cell carcinoma (RCC), pancreatic neuroendocrine tumors (pNETs), and retinal hemangioblastomas. Belzutifan, a hypoxia-inducible factor 2-alpha (HIF-2α) inhibitor, has demonstrated efficacy in treating VHL-associated tumors. This study evaluates our institutional experience with belzutifan in patients with VHL-related tumors. MATERIAL AND METHODS We conducted a retrospective cohort study across three Mayo Clinic sites, including patients aged ≥18 years with genetically confirmed VHL disease who received belzutifan between October 2021 and March 2025. Clinical/radiological data, and adverse events (AEs) were extracted from electronic health records. Tumor responses were assessed using RECIST v1.1 criteria for RCC, pNET, CNS hemangioblastoma. Retinal hemangioblastoma responses were evaluated through ophthalmologic assessments. RESULTS Forty-five patients were included (median age 44 58% female). Sixty-seven percent had RCC, 91% had CNS hemangioblastomas, 53% had pNETs, and 62% had retinal hemangioblastomas. The median duration of belzutifan therapy was 22.6 months (range 1.0-41.4 months). Among patients with RCC (n=26), overall response rate (ORR) was 19% and median time to best response (MTBR) was 7.4 months. Five patients had partial response (PR), 15 had stable disease (SD), and 1 had progressive disease (PD). For CNS hemangioblastomas (n=41), ORR was 12%, MTBR was 6.2 months. 5 patients had PR, 30 had SD, and none had PD. For pNET (n=17), ORR was 41%, MTBR was 8.2 months. One patient had CR, 6 patients had PR, 6 had SD, none had PD. For retinal hemangioblastomas (n=28), 6 (21%) showed improvement, 9 (32%) remained stable, and 3 (11%) showed progression. MTBR was 6.7 months. Treatment-related AEs occurred in 98% of patients. Common AEs included anemia (89%), fatigue (80%), hypoxia (18%), and headache (13%). Grade 3 AEs were observed in 20% of patients, including anemia (7%), hypoxia (9%), fatigue (4%), pneumonitis (2%), loss of consciousness (2%). One patient experienced a grade 4 event (status epilepticus). Anemia management involved iron supplementation (n=11), RBC transfusion (n=3), dose reduction (n=2), treatment holiday (n=8), permanent discontinuation (n=1). Hypoxia management included dose reduction (n=1), treatment holiday (n=3), discontinuation (n=1). CONCLUSION Belzutifan shows clinical activity across various VHL-associated neoplasms in real-world practice, with a manageable safety profile. The lower ORR compared to the phase III trial may reflect differences in baseline disease, including lower tumor burden in our cohort. These findings support its continued use in VHL disease, with attention to monitoring and managing treatment-related AEs.
B-162 Optimizing Thyroid Function Testing: Reducing Unnecessary Orders and Enhancing Patient Care Through Evidence-Based Cascade Algorithms
Terrio, Kim, Dangott, Bryan, Karon, Brad S. , Meroueh, Chady , Mundell, William, Sandleback, Sara, Meroueh, Chady , Sandleback, Sara G.

Mayo Clinic

Clinical Chemistry | October 2, 2025 | Volume: 71 | Issue: Supplement_1 | Pages: No page available

10.1093/clinchem/hvaf086.556 Get It

Abstract Background Thyroid function testing is a common laboratory service that can be optimized by implementing evidence-based algorithms. The thyroid function cascade testing approach at Mayo Clinic Labs is utilized to effectively evaluate and monitor functional thyroid status. The cascade begins with thyroid-stimulating hormone (TSH) as a screening marker. When TSH levels are normal, no additional testing is necessary. When the TSH result is abnormal, appropriate follow-up free T4, total T3, and/or TPO testing will automatically be performed. Providers at our institution can order thyroid function testing with this cascade testing approach or as standalone individual orderable tests. Initial data analysis showed patterns of TSH ordered concurrently with free T4, total T3, and/or anti-TPO. Further analysis revealed that a high number of concurrently ordered tests would not have been necessary had the algorithmic approach been followed. This opportunity for improvement led to the thyroid function testing initiative to direct providers to order the cascade test rather than individual thyroid tests, thereby reducing concurrent and unnecessary testing to improve patient care. Methods The initiative involved creating a new Epic order panel directing providers to order the cascade rather than the individual orderable tests. This intervention is a soft stop that allows providers to proceed by ordering individual tests if desired. We evaluated the impact of the initiative on test utilization, cost savings, and quality indicators using pre- and post-intervention data from all Mayo Clinic sites over a 9-month period. We compared the monthly volumes of concurrent and unnecessary orders of Free T4, Total T3, and TPO before and after the intervention. Concurrent orders were defined as tests collected from the same patient on the same date and time as TSH tests. Unnecessary orders were defined as tests that were outside the reflex range according to the thyroid function ordering algorithm. Cost savings were calculated based on the 2024 CMS reimbursement rates for the associated test CPT® codes. We also monitored and addressed feedback and requests from providers and laboratory staff throughout the initiative. Results The intervention resulted in a 20% average monthly reduction in concurrent orders and an 18% average monthly reduction in unnecessary orders of free T4, total T3, and anti-TPO tests. Estimated savings based on 2024 CMS reimbursement rates are $5,000 monthly and nearly $60,000 annually. Thyroid testing quality was also improved by aligning with clinical guidelines, reducing over-testing, and minimizing the risk of misdiagnosis. Conclusion The thyroid function testing initiative was a successful laboratory stewardship project that reduced redundant testing, improved patient care, and reduced costs. The initiative demonstrated the feasibility and effectiveness of using evidence-based reflex algorithms to optimize laboratory testing. The lessons learned include assessing all tests related to the disease condition to mitigate potential unintended increases in test usage and accounting for patient groups that are not covered by the intended algorithm*s target population. Future directions include expanding the cascade approach to other areas of laboratory medicine, evaluating the long-term outcomes of the initiative, and engaging with providers to ensure the adoption of the initiative.
Poster 46: Trends and Outcomes of Medial Ulnar Collateral Ligament Repair with Internal Brace, Isolated Reconstruction, and ’Hybrid’ Reconstruction with Internal Brace in Professional Baseball Players: A Matched Cohort Analysis
Griffith, Timothy B. , Chalmers, Peter N., Hebert, Elizabeth, Griffith, Timothy Bryan , Pan, Xuankang , Erickson, Brandon J. , Chalmers, Peter N. , Hebert, Elizabeth, Camp, Christopher L.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | September 26, 2025 | Volume: 13 | Issue: 9_suppl3 | Pages: No page available

10.1177/2325967125s00157 Get It

Objectives: There is a paucity of research comparing the outcomes of medial ulnar collateral ligament (MUCL) repair with internal bracing to isolated MUCL reconstruction in professional baseball players. Further, the practice of supplementing a MUCL reconstruction with an internal brace, a "hybrid" reconstruction, has increased in the surgical treatment of MUCL injuries for professional baseball players, without any currently known published research defining the clinical outcomes of this modification. We sought to investigate the trends and outcomes of MUCL repair with internal bracing and "hybrid" MUCL reconstruction with internal bracing. Using a matched cohort analysis, we also sought to compare the clinical outcomes of both MUCL repair with internal bracing and "hybrid" MUCL reconstruction with internal bracing to isolated MUCL reconstructions, without internal bracing, in professional baseball players. Methods: The MLB Health and Injury Tracking System was used to identify all professional baseball players who underwent MUCL surgery, regardless of surgery technique, from 2010 to 2023. Professional players of all levels (MLB and MiLB) and players of all positions were included. Player demographics, injury characteristics, surgical details, and postoperative outcomes were obtained. Player demographics included age at surgery, position of play, professional level of play and surgical technique. Outcomes assessed were return to play (RTP) status, time to RTP, return to same level of play (RTSL), time to RTSL, revision MUCL surgery, and time to revision MUCL surgery, with a minimum of 2 years of follow up. Players were considered to have RTP if they participated in at least one game at any professional level. RTSL was defined as returning to the same league of professional play or higher. Patients undergoing MUCL repair and "hybrid" MUCL reconstruction with internal bracing were independently compared to propensity matched patients undergoing isolated MUCL reconstruction, without internal bracing, to assess for a difference in postoperative outcomes. Four subgroup analyses were conducted by further categorizing patients to MLB players, MiLB players, pitchers, and position players. Results: 76 patients underwent MUCL repair with internal bracing from 2016-2021 and were successfully propensity matched to 76 patients undergoing isolated MUCL reconstructions. Baseline patient demographic variables of MUCL repairs were statistically similar to those of controls except for age at time of surgery (24.5 vs 21.8; p<0.001). 81 patients underwent "hybrid" MUCL reconstructions with internal bracing from 2016-2021 and were successfully propensity matched to 81 patients undergoing isolated MUCL reconstructions. Baseline demographic variables of "hybrid" MUCL reconstructions were statistically similar to those of controls except for age at time of surgery (24.3 vs. 23.3; p=0.006). Compared to isolated MUCL reconstruction controls, all patients undergoing MUCL repair demonstrated significantly shorter time to RTP (mean 421.2 vs. 546.2 days; p<0.001), shorter time to RTSL (mean 436.2 vs. 558.8 days; p<0.001), and shorter time to revision (mean 465.2 vs.1648 days; p=0.036). The number of patients who RTP at any level, RTSL, and number of revision surgeries were not significantly different. Compared to isolated MUCL reconstruction controls, all patients undergoing "hybrid" MUCL reconstructions demonstrated no significant differences with respect to the number of patients who RTP, time to RTP, number of patients who RTSL, days to RTSL, number of revision surgeries, and time to revision surgery. In MLB players only, compared to isolated MUCL reconstruction controls, patients who underwent MUCL repairs demonstrated significantly shorter time to RTP (mean 282.8 vs 507.3 days; p=0.008) and shorter time to RTSL (mean 299.7 vs. 598.0 days; p = 0.024). No other outcomes were significant. In MLB players only, compared to isolated MUCL reconstruction controls, patients who underwent "hybrid" MUCL reconstructions demonstrated significantly shorter time to RTP (mean 436.2 vs. 525.3 days; p=0.026). No other outcomes were significant. In MiLB players only, compared to isolated MUCL reconstruction controls, patients who underwent MUCL repairs demonstrated significantly shorter time to RTP (mean 444.3 vs 550.7 days; p<0.001) and shorter time to RTSL (mean 451.7 vs. 556.5 days; p<0.001). No other outcomes were significant. In MiLB players only, compared to isolated MUCL reconstruction controls, patients who underwent "hybrid" MUCL reconstructions demonstrated no significant differences in outcomes. In evaluating pitchers only, compared to isolated MUCL reconstruction controls, patients undergoing MUCL repair demonstrated significantly shorter time to RTP (mean 421.7 vs. 578.6 days; p<0.001), shorter time to RTSL (mean 434.8 vs. 591.6 days; p <0.001), and shorter time to revision surgery (mean 465.2 vs.1648 days; p=0.036). No other outcomes were significant. In pitchers only, compared to isolated MUCL reconstruction controls, patients undergoing "hybrid" MUCL reconstructions demonstrated significantly shorter time to RTP (mean 488.1 vs. 549.0 days; p=0.013) and shorter time to RTSL (mean 505.7 days vs. 577.0 days, respectively; p=0.021). No other outcomes were significant. Notably, all revision surgeries in occurred in pitchers only. Conclusions: Based on a matched cohort anaylsis of professional baseball players undergoing MUCL surgery, when compared to an isolated MUCL reconstruction, MUCL repair with internal bracing may allow for a shorter time to RTP and RTSL, with a shorter time to revision surgery. For pitchers, "hybrid" MUCL reconstruction may allow for a shorter time to RTP and RTSL. For MLB players, "hybrid" MUCL reconstruction may allow for a shorter RTP.
Poster 44: Outcomes of Revision Elbow Medial Ulnar Collateral Ligament Reconstruction in Professional Baseball Players: an Analysis of 191 Pitchers from 2010 to 2023
Chalmers, Peter N., Conte, Stan, Griffith, Timothy B. , Ma, Kevin , D’Angelo, John, Herbert, Liz, Simon, Karissa N. , Erickson, Brandon J. , Chalmers, Peter N. , Griffith, Timothy Bryan , D’Angelo, John, Herbert, Liz, Camp, Christopher L.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | September 26, 2025 | Volume: 13 | Issue: 9_suppl3 | Pages: No page available

10.1177/2325967125s00155 Get It

Objectives: The number of medial ulnar collateral ligament (MUCL) reconstructions are increasing. The epidemiology surrounding revision MUCL reconstructions in professional baseball players has not been well defined. The purpose of this study was to report the epidemiology of revision MUCL reconstruction in professional baseball players. The authors hypothesized that the number of revision MUCL reconstructions would increase over time and that the return to sport rate at the same level of play would be less than 70%. Methods: All professional baseball pitchers who underwent revision MUCL reconstruction between 2010-2023 were identified using the MLB Health and Injury Tracking System (HITS). Rate of return and time to return to play (RTP) and return to same level of play (RTSL) was recorded and analyzed for pitchers with a minimum follow up of 2 years. Surgical variables including technique and graft choice were also recorded. Results: Overall, 191 pitchers (avg age 26.0 years), underwent revision MUCL reconstruction. The average time between primary and revision surgery was 1,381 days (45 months). 130 (68%) of these players were MLB pitchers and the other 61 (32%) were MiLB pitchers. 59% of pitchers were able to RTSL at an average of 604 ± 250 days after surgery. 2023 was the year with most revision MUCL reconstructions (n = 27) and the fewest reconstructions were performed in 2010 and 2011 (n = 4). Monthly distribution demonstrates the highest surgery months to be May (17%), June (20%), and July (17%). Hamstring tendon autograft was found to be the most commonly used graft source (n = 90, 47%), compared to palmaris longus autograft (n = 67, 35%). No significant differences were found in the types of grafts used over time ( P = .238 for palmaris and P = .133 for hamstring). In terms of tunnel configuration, both the Modified Jobe and Docking techniques were used in equal occurrence (n = 70, 37%) Conclusions: Following revision MUCL reconstruction, only 72% of professional baseball pitchers were able to return to play at any level at an average of 556 days (18 months), and only 59% were able to return to the same level of play at an average of 604 days (20 months). The average time between primary and revision MUCL reconstruction was 45 months (3.75 years). Pitchers should be counseled on the relatively low RTSL rate and the prolonged time to RTSL.
Poster 52: Epidemiology of Ulnar Collateral Ligament Surgeries in Major and Minor League Baseball Pitchers: A Comprehensive Report of 2,287 Cases
Meta, Fabien , Meister, Keith, Griffith, Timothy B. , Chalmers, Peter N., Mavrommatis, Sophia , Griffith, Timothy Bryan , Chalmers, Peter N. , Clark, Sean C. , Camp, Christopher L.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | September 26, 2025 | Volume: 13 | Issue: 9_suppl3 | Pages: No page available

10.1177/2325967125s00163 Get It

Objectives: The medial ulnar collateral ligament (MUCL) is the primary stabilizer of valgus forces across the elbow. Injury to the MUCL has a large impact on the throwing athlete, particularly in baseball. The incidence of MUCL injury in baseball pitchers is on the rise. Surgical treatment and rehabilitation is evolving to improve outcomes and improve return to sport time frames. The purpose of this study was to highlight the trends in MUCL repair and reconstruction in professional baseball pitchers, describe relevant outcomes such as return to any level of play (RTP) for surgical repair and reconstruction, and distinguish what factors might impact these outcomes. The authors hypothesize that primary and revision MUCL surgery is increasing with revision surgery requiring the greatest time to RTP. Methods: The Major League Baseball (MLB) Health and Injury Tracking System (MLB HITS) database was used to procure data during the targeted study period (2010 – 2023). All professional pitchers who underwent MUCL surgery within the study period were included. Variables analyzed included age, career length, and level of play. Surgical variables included date and type of procedure, RTP status, time required to RTP, return to same level of play (RTSL), career length before and after surgery, number of revision surgeries, and time between surgeries. Successful RTP was designated if a pitcher had returned in at least one professional game after index surgery. Analyses of trends over time were performed. The year 2020 was considered an outlier and omitted from the analysis of trends due to the coronavirus pandemic which limited games played. Results: A total of 2,287 pitchers underwent MUCL surgery during the study period (Table 1). The annual number of MUCL surgeries on all pitchers increased year over year (R 2 = 0.821, p < 0.001), as did the annual number of reconstructions with internal brace (IB) augmentation (R 2 = 0.896, p < 0.001) (Figure 1). The RTP rate (93%) for MLB pitchers was significantly higher compared to the RTSL rate (71%, P < 0.001). This difference was not observed in Minor League Baseball (MiLB) (RTP 76% vs. RTSL 74%, P = 0.142) (Figure 2). The percentage of players who RTP after revision surgery was significantly lower compared to primary surgery (71%vs. 80% respectively, P = 0.020). Mean time to RTP is significantly shorter (470 ± 135 days) compared to the mean time to RTSL (499 ± 153 days, P < 0.001) (Figure 3). The annual number of revision MUCL surgeries on all pitchers increased year over year as well (R 2 = 0.322, p = 0.043). Conclusions: MUCL surgery continues to increase, also leading to increasing numbers of revisions in professional pitchers. Overall, 80% of pitchers were able to RTP at a mean of 470 days (15.5 months), while only 71% were able to RTSL at a mean of 499 days (16.5 months), but this varied based on level of play. Surgical techniques continue to evolve as MUCL repairs and reconstructions with IB augmentation have increased significantly in recent years. This study will help guide athlete expectations and surgeon decision-making.
Why don’t more physicians use osteopathic manipulative medicine? A cross-sectional study of utilization and referral barriers
Stacey, Stephen K , Furlano, Anthony, Genewick, Joanne, Westfall, Erin , Gordon, Bryan, Toor, Jiwan, Westfall, Erin , Gordon, Bryan, Toor, Jiwan

Mayo Clinic

Journal of Osteopathic Medicine | September 18, 2025 | Volume: 126 | Issue: 4 | Pages: 181-189

10.1515/jom-2025-0062 | PMID 40966192 Get It

Abstract Context Evidence supports osteopathic manipulative medicine (OMM) as an effective manual therapy, although it remains underutilized by Doctors of Osteopathic Medicine (DOs). Objectives Understanding barriers preventing the broader adoption of OMM is essential to expanding access to it as a noninvasive treatment option. We set out to survey both DOs and non-DO clinicians to identify perceived barriers to OMM. Methods Survey items were adapted from prior studies utilizing an iterative refinement process that included cycles of pilot testing with revisions. Participants were recruited internally from Mayo Clinic Midwest – a large, multistate, healthcare system in the Midwest region of the United States – utilizing internal email. Participants were given a descriptive survey that was developed with support from the Mayo Clinic Survey Research Center. Results The survey was sent out to a total of 952 individuals, including 184 DOs and 768 non-DO clinicians (MD, Bachelor of Medicine, Bachelor of Surgery [MBBS], nurse practitioners, and physician assistants). Respondents included 76 DOs (41.3 % response rate) and 91 non-DOs (11.8 % response rate). Of the 76 DO respondents, 21 (27.6 %) reported utilizing OMM clinically. Commonly reported barriers include time limitations, poor public perception, and lack of training in residency, and time is allocated to other professional interests. Conclusions Within a large health system that includes primary care and specialty care, few DOs practice OMM, citing time constraints, lack of residency training, and competing professional interests as primary barriers. These challenges might successfully be addressed through targeted osteopathic manipulative treatment (OMT) education in residency programs, enhanced compensation, and improved referral pathways.